Cost to insure Bristol-Myers debt jumps as leverage balloons


The cost to insure Bristol-Myers Squibb debt hit its highest point since May 2010 on Thursday, following the announcement that the U.S. pharmaceutical company would acquire rival Celgene Corp in a deal worth about $74 billion.